Please login to the form below

Not currently logged in
Email:
Password:

Jardiance

This page shows the latest Jardiance news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

established drugs Johnson &Johnson’s first-to-market blockbuster Invokana (canagliflozin) - which brought in more than $1.2bn last year - fast-gaining rival Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim

Latest news

More from news
Approximately 17 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics